Intuitive Surgical Inc (ISRG)

[TREND1]

PE Ratio = 60.90

[TREND1]

Earnings Per Share (EPS) =6.40

[TREND1]

Profit/Loss = $ 735.9M

[TREND1]

ISRG DAY

[Phaeton]

Companies like intuitive are few and far between. Mazor might just be another one that really makes it big. But they needed help and Medtronic provided that help with Sales & Marketing and a Buy in.

But there are many other small companies that will not make it and run out of capital. I have invested in them and have lost.

Maybe ISRG will take a run at buying into or buying out some of the others that are just breaking into the space but for every ten that try to make it only a couple of them due like ISRG.

The others will name make it to the finish line and run out of cash trying to get FDA approval.

[Phaeton]

Amazing company. Shareholder since 2010 and have to say that I wish that I had more shares. Pre-split is $1,185.00 today. Amazing.

[biotechnician]

FYI, MZOR Market cap only 1.5 Billion and ISRG's is 41 Billion. MZOR stock price can Double and still just be 3 Billion MC.

[dshade]

pulled the trigger today. nice run, wow

[SPORT19]

An incredible run by a fantastic company. Congratulations to all who invested in ISRG!
I'm looking for thoughts on upcoming competition. I've invested in Titan Medical. I saw their SPORT system at the SAGES conference in Boston last year. Looked like a winning design. Do you see this as a viable competitor to DaVinci?

[Fibanotch]

robotic

[nlightn]

Fibanotch,...your post is kind of cryptic,...'cyber knife'.

if i might ask, what are you referring to or referencing ?,...

and how does 'cyber knife' have to do with ISRG ?

TIA for your reply

[Fibanotch]

cyber knife

[annabelletrader]

Investors should be aware that Intuitive Surgical, Inc. (NASDAQ:ISRG) reports earnings Tuesday, January 24th, 2017, after the stock market closes. After studying the stock chart for some time, it looks like odds favor an earnings beat and upside move. This is seen by viewing the bull-like flag consolidation that is currently underway. It signals accumulation and digestion of the latest up move. The upside is pretty substantial with $720.00 as a target. The current price of Intuitive Surgical is $655.00. Earnings are expected to be $6.21 per shares on revenue of $738 million. Please be aware, IF I decide to take the risk and play this trade, I will most likely limit my risk by grabbing a few call options.


Investors expect bullish earnings from Intuitive Surgical

[ValueInvestor15]

What i'm looking at before earnings today. Intuitive Surgical up almost 50% over the last year. Edwards lifesciences the only other stock that high...


chart


Fundamentals imply shares are trading at 10% premium to its Fair Value


Fair Value

Not a fan of the margin of safety here before earnings

[shub]

Looks like an ISRG copycat with the haptics and eye-sensing camera control i suggested ISRG acquire years ago..
Gonna have to be equivalent and really cheap to compete.

[Eagleize]

Check out TRXC. Could start trading like ISRG

[Hypocrates]

ISRG should buy out Titan Medical. Check out this next generation Beaut!

[Jenkens]

Insiders sold 70,452 shares in the last three months and 223,856 shares in the past year. source: http://www.nasdaq.com/symbol/isrg/ownership-summary

EPS expectations are 0.23% lower than that of Wall Street for $ISRG Q2 [Reporting 07/19 AMC]
https://www.estimize.com/intro/isrg?utm_content=ISRG&utm_medium=eps_update&utm_source=stocktwits#chart=historical

Bullish trend likely continue shortly after a pullback.

[was CUIN2]

Intuitive Surgical has been the leader in the surgical robotic market for the past 15 years, but two new surgical robotic systems are expected to come to the market this year. Those systems are Titan Medical’s SPORT system, which is for general abdominal, gynecologic, urologic and colorectal procedures, and TransEnterix’s SurgiBot robotic system, which doesn’t have any known indications yet.

https://m.dotmed.com/news/story/29980

[was CUIN2]

There is a lot of opportunity existing for Titan Medical and the SPORT Surgical System. Today they unveil the platform at SAGE's.

[was CUIN2]

Lol. It's been a long time coming..

[BIGKAHUNA57]

SPORT 2 B unveiled & demo'd at SAGES 2016.

Regards,
BK

[dannyzee84]

Cmon baby... 20%+ move on this ER!!

[mick]

this is huge read here , thank you. 'Intuitive Surgical Inc (ISRG)'

[jimmybob]

$600+ stock in $500 clothing

[mick]

Intuitive Surgical, (ISRG)
508.44 ? -5.6183 (-1.09%)
Volume: 210,412 @ 4:44:14 PM ET

Bid Ask Day's Range
498.01 533.87 506.24 - 511.57

ISRG Detailed Quote Wiki

[mick]

what you have on recent stuff for 'Intuitive Surgical Inc (ISRG)'



re;
Webinar: My Top 5 Stocks/Themes heading into 2015 - 2014 top stocks gained 25.6% vs 12.6% for S&P : http://www.optionmillionaires.com/top-5-stocks-top-5-themes-2015-webinar-december-29th-2014-430pm/ $ISRG $SCTY

[mick]

[mick]

ISRG Intuitive Surgical Inc

275 8 months ago Medical - Equipment

http://investorshub.advfn.com/Intuitive-Surgical-Inc-ISRG-3862/

ISRG News: Statement of Changes in Beneficial Ownership (4) 09/02/2015 05:29:25 PM
ISRG News: Statement of Changes in Beneficial Ownership (4) 08/19/2015 05:32:28 PM
ISRG News: Statement of Changes in Beneficial Ownership (4) 08/18/2015 04:08:27 PM
ISRG News: Statement of Changes in Beneficial Ownership (4) 08/18/2015 04:05:09 PM
ISRG News: Statement of Changes in Beneficial Ownership (4) 08/18/2015 04:02:04 PM

[starbuxsux]

Intuitive Surgical Announces Fourth Quarter Earnings

4:05 PM ET 1/22/15 | GlobeNewswire

Intuitive Surgical, Inc. (Nasdaq:ISRG), the industry leader in robotic-assisted surgery, today announced financial results for the quarter ended December 31, 2014. Reported revenue and procedures were consistent with the January 13 press release.

Q4 Highlights

-- Worldwide da Vinci procedures grew approximately 10% over the fourth quarter of 2013, driven by growth in U.S. general surgery procedures and worldwide urologic procedures.

-- The Company placed 137 da Vinci Surgical Systems, compared to 138 in the fourth quarter of 2013 and 111 in the third quarter of 2014.

-- Non-GAAP* revenue of $601 million for the quarter grew approximately 4% compared with $576 million last year.

-- Fourth quarter 2014 non-GAAP* net income was $184 million, or $4.92 per diluted share, compared with $193 million, or $4.98 per diluted share, for the fourth quarter of 2013.

-- The Company increased sales of the recently introduced da Vinci Xi System to 97 in the fourth quarter of 2014, compared to 59 in the third quarter of 2014, and 50 during the second quarter of 2014, the quarter of launch.

-- The Company received regulatory clearance and began to sell the da Vinci Xi System in Korea in the fourth quarter of 2014.

-- The Company launched its wristed Single Site needle driver in the fourth quarter of 2014.

Q4 Financial Summary

Revenue, gross profits, income from operations, net income, and net income per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and are reconciled to the corresponding GAAP measures at the end of this release.

Revenue in the fourth quarter of 2014 was $605 million, an increase of approximately 5% compared with $576 million in the fourth quarter of 2013. Non-GAAP revenue in the fourth quarter was $601 million, an increase of approximately 4% compared with $576 million in the fourth quarter of 2013. Non-GAAP revenue excludes $4 million of net revenue associated with da Vinci Xi System trade-out offers.

Fourth quarter 2014 instrument and accessory revenue increased by approximately 5% to $281 million compared with $268 million for the fourth quarter of 2013. Instrument and accessory revenue on a non-GAAP basis increased to $280 million in the fourth quarter of 2014 compared to $268 million in the fourth quarter of 2013. Non-GAAP instrument and accessory revenue excludes $1 million of net revenue associated with da Vinci Xi System trade-out offers.

Systems revenue increased to $214 million in the fourth quarter of 2014, compared with $205 million for the fourth quarter of 2013. Systems revenue on a non-GAAP basis increased to $211 million in the fourth quarter of 2014, compared with $205 million for the fourth quarter of 2013. Non-GAAP systems revenue excludes $3 million of net revenue associated with da Vinci Xi System trade-out offers. Intuitive Surgical placed 137 da Vinci Surgical Systems in the fourth quarter of 2014, compared with 138 in the same period last year.

Fourth quarter 2014 service revenue increased approximately 6% to $110 million, compared with $103 million for the fourth quarter of 2013, reflecting growth in the installed base of da Vinci Surgical Systems. GAAP and non-GAAP service revenue was the same in both quarters.

Fourth quarter 2014 income from operations decreased to $186 million, compared with $209 million in the fourth quarter of 2013. Fourth quarter 2014 non-GAAP income from operations decreased to $237 million, compared with $255 million in the fourth quarter of 2013.

Fourth quarter 2014 GAAP net income was $147 million, or $3.94 per diluted share, compared with $166 million, or $4.28 per diluted share, for the fourth quarter of 2013. Fourth quarter 2014 non-GAAP net income was $184 million, or $4.92 per diluted share, compared with $193 million, or $4.98 per diluted share, for the fourth quarter of 2013. Net income for the fourth quarter of 2014 included $20 million of income tax reserve releases.

Full year 2014 GAAP and non-GAAP revenue was $2.1 billion, compared to $2.3 billion in 2013. Full year 2014 net income per diluted share was $11.11, compared to $16.73 in 2013 and full year 2014 non-GAAP diluted net income per share was $16.10, compared to $19.83 in 2013.

Intuitive Surgical ended the fourth quarter of 2014 with $2.5 billion in cash, cash equivalents, and investments, an increase of $234 million during the quarter, primarily driven by cash generated from operations.

Commenting on the announcement, Dr. Gary Guthart, President and CEO of Intuitive Surgical, said, "We are pleased with our fourth quarter procedure and da Vinci system placement results which reflect an increase in the use of our products in general surgery, growing demand for our da Vinci Xi System and increased adoption in Europe and other international markets."

Additional supplemental financial and procedure information has been posted to the Investor Relations section of the Intuitive website at: http://phx.corporate-ir.net/phoenix.zhtml?c=122359&p=irol-IRHome.

Webcast and Conference Call Information

Intuitive Surgical will hold a teleconference at 1:30 p.m. PST today to discuss the fourth quarter 2014 financial results. The call is being webcast by NASDAQ OMX and can be accessed at Intuitive Surgical's website at www.intuitivesurgical.com or by dialing [phone] or [phone].

About Intuitive Surgical, Inc.

Intuitive Surgical, Inc. (Nasdaq:ISRG), headquartered in Sunnyvale, Calif., is the global leader in robotic-assisted, minimally invasive surgery. Intuitive Surgical develops, manufactures and markets the da Vinci Surgical System. Intuitive Surgical's mission is to extend the benefits of minimally invasive surgery to those patients who can and should benefit from it.

About the da Vinci Surgical System

The da Vinci Surgical System is a surgical platform designed to enable complex surgery using a minimally invasive approach. The da Vinci Surgical System consists of an ergonomic surgeon console or consoles, a patient-side cart with three or four interactive arms, a high-performance vision system and proprietary EndoWrist(R) instruments. Powered by state-of-the-art technology, the da Vinci Surgical System is designed to scale, filter and seamlessly translate the surgeon's hand movements into more precise movements of the EndoWrist instruments. The net result is an intuitive interface with improved surgical capabilities. By providing surgeons with superior visualization, enhanced dexterity, greater precision and ergonomic comfort, the da Vinci Surgical System makes it possible for skilled surgeons to perform more minimally invasive procedures involving complex dissection or reconstruction. For more information about clinical evidence related to da Vinci Surgery, please visit www.intuitivesurgical.com/company/clinical-evidence/.

da Vinci(R) and EndoWrist(R) are trademarks of Intuitive Surgical, Inc.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding increased use of our products in general surgery, growing demand for the da Vinci Xi System, and increased adoption in Europe and other international markets. These forward-looking statements are necessarily estimates reflecting the best judgment of our management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These forward-looking statements should, therefore, be considered in light of various important factors, including, but not limited to, the following: the impact of global and regional economic and credit market conditions on health care spending; health care reform legislation in the United States and its impact on hospital spending, reimbursement and fees which will be levied on certain medical device revenues; decreases in hospital admissions and actions by payers to limit or manage surgical procedures; timing and success of product development and market acceptance of developed products; procedure counts; regulatory approvals, clearances and restrictions or any dispute that may occur with any regulatory body; guidelines and recommendations in the health care and patient communities; intellectual property positions and litigation; competition in the medical device industry and in the specific markets of surgery in which we operate; unanticipated manufacturing disruptions or the inability to meet demand for products; the results of legal proceedings to which we are or may become a party; product liability and other litigation claims; adverse publicity regarding the Company and the safety of our products and adequacy of training; our ability to expand into foreign markets; and other risk factors under the heading "Risk Factors" in our report on Form 10-K for the year ended December 31, 2013, as updated by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. Statements using words such as "estimates," "projects," "believes," "anticipates," "plans," "expects," "intends," "may," "will," "could," "should," "would," "targeted" and similar words and expressions are intended to identify forward-looking statements. You are cautioned not to place undue reliance on these forward looking statements, which speak only as of the date of this press release. We undertake no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.

*About Non-GAAP Financial Measures

To supplement our consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States ("GAAP"), we use the following non-GAAP financial measures: non-GAAP revenue, non-GAAP gross profit, non-GAAP income from operations, non-GAAP net income, and non-GAAP net income per share ("EPS"). The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

We use these non-GAAP financial measures for financial and operational decision-making and as a mean to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance and liquidity by excluding non-cash charges, such as amortization of intangible assets and share-based compensation ("SBC") expenses, and other special items. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management's internal comparisons to our historical performance and liquidity as well as comparisons to our competitors' operating results. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the performance of our business.

Non-GAAP revenue. We define non-GAAP revenue as revenue excluding the impact of reserve adjustments recorded in connection with trade-in rights provided to certain customers in connection with the launch of our da Vinci Xi Surgical System that are accounted for as a right of return.

Non-GAAP gross profit. We define non-GAAP gross profit as gross profit excluding the amortization of intangible assets, expenses related to SBC, and the impact of revenue and costs deferred in connection with trade-in rights provided to certain customers in connection with the launch of our da Vinci Xi Surgical System that are accounted for as a right of return.

Non-GAAP income from operations. We define non-GAAP income from operations as income from operations excluding the amortization of intangible assets, expenses related to SBC, and other special items.

Non-GAAP net income and EPS. We define non-GAAP net income as net income excluding the amortization of intangible assets, expenses related to SBC, non-cash impairment of investments, and other special items, net of the related tax effects. The tax effects are determined by applying a calculated non-GAAP effective tax rate, which is commonly referred to as the with-and-without method. Without excluding these tax effects, investors would only see the gross effect that excluding these expenses had on our operating results. We define non-GAAP EPS as non-GAAP net income divided by the weighted average outstanding shares, on a fully-diluted basis.

There are a number of limitations related to the use of non-GAAP measures versus measures calculated in accordance with GAAP. Non-GAAP gross profit, non-GAAP income from operations, non-GAAP net income, and non-GAAP EPS exclude amortization of intangible assets and SBC, which are recurring expenses. SBC has been and will continue to be for the foreseeable future a significant recurring expense in our business. In addition, the components of the costs that we exclude in our calculation of non-GAAP net income and non-GAAP EPS may differ from the components that our peer companies exclude when they report their results of operations. Management compensates for these limitations by providing specific information regarding the GAAP amounts excluded from non-GAAP net income and non-GAAP EPS and evaluating non-GAAP net income and non-GAAP EPS together with net income and EPS calculated in accordance with GAAP.

View data
INTUITIVE SURGICAL, INC. UNAUDITED QUARTERLY CONSOLIDATED STATEMENTS OF INCOME (IN MILLIONS, EXCEPT PER SHARE DATA) Three months ended In millions (except per share data) December 31, September 30, December 31, 2014 2014 2013 Revenue: Instruments and accessories $280.7 $272.8 $268.2 Systems 214.0 168.8 204.6 Services 110.0 108.5 103.4 Total revenue 604.7 550.1 576.2 Cost of revenue: Product 172.3 150.3 144.2 Service 39.0 39.2 34.0 Total cost of revenue 211.3 189.5 178.2 Gross profit 393.4 360.6 398.0 Operating expenses: Selling, general, and administrative 160.0 154.0 147.7 Research and development 47.3 47.5 41.7 Total operating expenses 207.3 201.5 189.4 Income from operations 186.1 159.1 208.6 Interest and other income (expense), net (1.3) 2.0 5.9 Income before taxes 184.8 161.1 214.5 Income tax expense 38.0 37.4 48.3 Net income $146.8 $123.7 $166.2 Net income per share: Basic $4.03 $3.43 $4.36 Diluted $3.94 $3.35 $4.28 Shares used in computing net income per share: Basic 36.4 36.1 38.1 Diluted 37.3 36.9 38.8

View data
INTUITIVE SURGICAL, INC. UNAUDITED TWELVE MONTHS ENDED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (IN MILLIONS, EXCEPT PER SHARE DATA) Twelve months ended December 31, In millions (except per share data) 2014 2013 Revenue: Instruments and accessories $1,070.2 $1,032.9 Systems 632.5 834.9 Services 429.0 397.3 Total revenue 2,131.7 2,265.1 Cost of revenue: Product 569.9 543.4 Service 148.0 127.5 Total cost of revenue 717.9 670.9 Gross profit 1,413.8 1,594.2 Operating expenses: Selling, general, and administrative 691.0 574.0 Research and development 178.0 167.7 Total operating expenses 869.0 741.7 Income from operations 544.8 852.5 Interest and other income, net 4.2 18.4 Income before taxes 549.0 870.9 Income tax expense 130.2 199.9 Net income $418.8 $671.0 Net income per share: Basic $11.35 $17.12 Diluted $11.11 $16.73 Shares used in computing net income per share: Basic 36.9 39.2 Diluted 37.7 40.1

View data
INTUITIVE SURGICAL, INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (IN MILLIONS) In millions December 31, December 31, 2014 2013 Cash, cash equivalents and investments $2,497.0 $2,753.9 Accounts receivable, net 315.1 301.4 Inventories 181.7 179.6 Property, plant and equipment, net 387.4 309.9 Goodwill 198.0 137.4 Deferred tax assets 171.3 135.7 Other assets 208.9 132.4 Total assets $3,959.4 $3,950.3 Accounts payable and other accrued liabilities $358.1 $247.2 Deferred revenue 221.9 201.7 Total liabilities 580.0 448.9 Stockholders' equity 3,379.4 3,501.4 Total liabilities and stockholders' equity $3,959.4 $3,950.3

View data
INTUITIVE SURGICAL, INC. UNAUDITED RECONCILIATION OF GAAP FINANCIAL MEASURES TO NON-GAAP FINANCIAL MEASURES (IN MILLIONS, EXCEPT PER SHARE DATA) Three Months Ended Twelve months ended In millions (except per share data) December 31, September 30, December 31, December 31, December 31, 2014 2014 2013 2014 2013 GAAP revenue $604.7 $550.1 $576.2 $2,131.7 $2,265.1 Deferral (recognition) of revenue related to Xi trade-out offers (3.9) (16.0) -- -- -- Non-GAAP revenue $600.8 $534.1 $576.2 $2,131.7 $2,265.1 GAAP gross profit $393.4 $360.6 $398.0 $1,413.8 $1,594.2 Xi trade-out offers (2.2) (13.9) -- -- -- Share-based compensation expense 8.4 8.8 7.6 32.6 30.3 Amortization of intangible assets 3.6 3.6 2.0 10.8 10.4 Non-GAAP gross profit $403.2 $359.1 $407.6 $1,457.2 $1,634.9 GAAP income from operations $186.1 $159.1 $208.6 $544.8 $852.5 Xi trade-out offers (2.2) (13.9) -- -- -- Share-based compensation expense 41.2 45.2 41.6 169.1 168.9 Amortization of intangible assets 6.5 6.5 4.7 22.4 21.3 Product liability litigation charges 5.4 -- -- 82.4 -- Non-GAAP income from operations $237.0 $196.9 $254.9 $818.7 $1,042.7 GAAP net income $146.8 $123.7 $166.2 $418.8 $671.0 Xi trade-out offers (2.2) (13.9) -- -- -- Share-based compensation expense 41.2 45.2 41.6 169.1 168.9 Amortization of intangible assets 6.5 6.5 4.7 22.4 21.3 Product liability litigation charges 5.4 -- -- 82.4 -- Impairment of investments 4.3 -- -- 8.5 -- Tax adjustments (18.5) (16.8) (19.1) (94.3) (66.2) Non-GAAP net income $183.5 $144.7 $193.4 $606.9 $795.0 GAAP net income per share - diluted $3.94 $3.35 $4.28 $11.11 $16.73 Xi trade-out offers (0.06) (0.38) -- -- -- Share-based compensation expense 1.10 1.22 1.07 4.49 4.21 Amortization of intangible assets 0.17 0.18 0.12 0.59 0.53 Product liability litigation charges 0.14 -- -- 2.19 -- Impairment of investments 0.12 -- -- 0.23 -- Tax adjustments (0.49) (0.45) (0.49) (2.51) (1.64) Non-GAAP net income per share - diluted $4.92 $3.92 $4.98 $16.10 $19.83

CONTACT: Investor Relations
[phone]

http://media.globenewswire.com/cache/7637/small/27347.jpg

http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAxMTY2MTcjNzYzNw==

[jimmybob]

Webinar: My Top 5 Stocks/Themes heading into 2015 - 2014 top stocks gained 25.6% vs 12.6% for S&P : http://www.optionmillionaires.com/top-5-stocks-top-5-themes-2015-webinar-december-29th-2014-430pm/ $ISRG $SCTY

[jimmybob]

FDA updates warning on laparoscopic power morcellators to treat uterine fibroids
The FDA announced it is taking immediate steps to help reduce the risk of spreading unsuspected cancer in women being treated for uterine fibroids. In an updated safety communication, originally issued in April, the FDA warns against using laparoscopic power morcellators in the removal of the uterus or fibroids in the vast majority of women. In an Immediately in Effect guidance, the FDA is also recommending that manufacturers of laparoscopic power morcellators include in their product labeling specific safety statements in the form of a boxed warning and two contraindications. Johnson & Johnson (JNJ), the largest manufacturer of morcellators, stopped selling the gynecological surgical tool in April and in August told customers to return any devices in their inventory. Intuitive Surgical's (ISRG) da Vinci surgical system can be used with tissue morcellators in such surgical procedures

[stocktrademan]

$ISRG DD Notes ~ http://www.ddnotesmaker.com/ISRG

bullish very long term

$ISRG recent news/filings

## source: finance.yahoo.com

Tue, 28 Oct 2014 22:57:00 GMT ~ Medical Equipment Stocks Rise; Idexx Clears Buy Point


read full: http://news.investors.com/102814-723817-medical-equipment-group-jumps-up-ibd-industry-ranks.htm?ven=yahoocp&src=aurlled&ven=yahoo
*********************************************************

Tue, 28 Oct 2014 18:39:00 GMT ~ Bonds hold losses after weak 2-year note auction


read full: http://www.cnbc.com/id/102126554?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=102126554
*********************************************************

Fri, 24 Oct 2014 21:50:00 GMT ~ Can Fat-Freezer Zeltiq Aesthetics Heat Up Profits?


read full: http://news.investors.com/102414-723425-zeltiq-aesthetics-is-starting-to-rebound.htm?ven=yahoocp&src=aurlled&ven=yahoo
*********************************************************

Thu, 23 Oct 2014 19:42:55 GMT ~ INTUITIVE SURGICAL INC Files SEC form 10-Q, Quarterly Report


read full: http://biz.yahoo.com/e/141023/isrg10-q.html
*********************************************************

Wed, 22 Oct 2014 20:28:00 GMT ~ As earnings season heats up, stocks close on the lows…


read full: http://finance.yahoo.com/tumblr/blog-as-earnings-season-heats-up-stocks-close-on-the-lows-202816034.html
*********************************************************


$ISRG charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$ISRG company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ISRG/company-info
Ticker: $ISRG
OTC Market Place: Not Available
CIK code: 0001035267
Company name: Intuitive Surgical, Inc.
Company website: http://www.intuitivesurgical.com
Incorporated In: DE, USA


$ISRG share structure

## source: otcmarkets.com

Market Value: $17,824,718,837 a/o Oct 28, 2014
Shares Outstanding: 36,251,945 a/o Oct 13, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
$ISRG extra dd links

Company name: Intuitive Surgical, Inc.
Company website: http://www.intuitivesurgical.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ISRG/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ISRG/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ISRG+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ISRG+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ISRG+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ISRG/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ISRG/news - http://finance.yahoo.com/q/h?s=ISRG+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ISRG/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ISRG/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ISRG/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ISRG/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ISRG/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ISRG/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ISRG/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ISRG/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ISRG+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ISRG
DTCC (dtcc.com): http://search2.dtcc.com/?q=Intuitive+Surgical%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Intuitive+Surgical%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Intuitive+Surgical%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.intuitivesurgical.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.intuitivesurgical.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.intuitivesurgical.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ISRG/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ISRG
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ISRG/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ISRG/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ISRG/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001035267&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ISRG/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ISRG/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ISRG/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ISRG/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ISRG&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ISRG
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ISRG/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ISRG+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ISRG+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ISRG
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ISRG
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ISRG+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ISRG/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ISRG+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ISRG.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ISRG
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ISRG/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ISRG/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ISRG/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ISRG/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ISRG
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ISRG
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ISRG:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ISRG
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ISRG



$ISRG DD Notes ~ http://www.ddnotesmaker.com/ISRG

[SuperVeloce]

What's this going to?

[Phaeton]

Nice pop last night. Glad it held on too. I have had ISRG for about 5 years. Great stock but has a Jekyell and Hyde side to it.

I also have some stock in a Intuitive want to be called Titan Medical. TITXF They are just in the begining stages and are about 15 to 24 months before getting FDA approval. So Intuitive does not have much to worry about yet.

Can we get ISRG back to the $600.00 range?

[RealGenius]

400K shares AH

[Renaissance18]

http://seekingalpha.com/article/2290213-mazor-robotics-outstanding-company-few-investors-know-exists

[was CUIN2]

NEW YORK (Reuters) - Investors can expect a surge in volume at the close of trading on Friday, when Russell Investments announces the annual rebalance of its series of indexes that will affect more than $5 trillion in assets.

The reconstitution requires asset managers to adjust their portfolios to align with indexes such as the small-cap Russell 2000 (.RUT) and the Russell 3000 (.RUA), which represents most of the largest publicly traded U.S. companies.

[was CUIN2]

Is Intuitive Surgical An Undervalued Stock Or A Value Trap?
Monday, May 12, 12:00 PM ET | About: ISRG

Victor Liang
Victor is a co-founder of Intelligent Stocks Inc., a stock recommendation service that is dedicated to helping investors outperform the market. He started writing about stocks and publishing his stock picks in January 2013, which have outperformed the S&P 500 since inception. He believes that "investment is most intelligent when it is most businesslike" as stated by Benjamin Graham. He learned to invest by investing in the stock market, and by reading Warren Buffett's annual letter to shareholders, Benjamin Graham's The Intelligent Investor and dozens of company annual reports. He is currently studying for CFA Level I and will be taking the exam in December this year. In his spare time, he enjoys sharing his investing ideas with his friends, jogging for more than an hour and spending time with his partner. He has also published a free eBook called 'How to Outperform the Market'.
Summary

Intuitive Surgical has dropped substantially since 2013 due to various economic and regulatory conditions.
The company's earnings will likely disappoint further throughout 2014 according to management's Q1 2014 conference call.
The stock is still overvalued relative to its intrinsic value.
The stock is likely a value trap in the short-term but it should eventually recover as U.S. procedure growth improves and as the company expands more in new procedures.
Intuitive Surgical (ISRG), the maker of the da Vinci Surgical System, is the leading robotic surgical company in the world, dominating the robotic surgical industry. In fact, the company has a near monopoly because its patented technologies are far ahead of its competitors - Titan Medical (OTCQX:TITXF), TransEnterix (OTCQB:TRXC), SOFAR S.P.A. - and its da Vinci Surgical System is among the best in the industry. The company competes primarily with "open surgery procedures, conventional Minimally Invasive Surgery (MIS), drug therapies, radiation treatment" and other procedures that do not use robotic surgical systems (source: 2013 Annual Report).

ISRG's revenue growth was superb over the past ten years. The company's revenue grew from $139 million in fiscal 2004 to $2,265 million in fiscal 2013 (see image below), which resulted in a compound annual growth rate of 36% each year. Moreover, ISRG is not a capital intensive company. It generates millions of dollars of free cash flow each year that is often used for share buybacks. The company earns its revenue from selling da Vinci Surgical Systems to hospitals (aka unit sales) and from the sale of da Vinci surgical instruments, accessories and services (aka recurring revenue).

(click to enlarge)


However, the stock plunged substantially since the beginning of 2013 for several economic and regulatory reasons:

The U.S. Preventive Services Task Force's recommendation against prostate-specific antigen screening and treatment changes for low risk prostate cancer have led to ISRG's decline in da Vinci's Prostatectomy business (source: 2013 Annual Report).
Changing surgical admissions and lower growth in gynecologic procedures.
Negative media about da Vinci procedures and liability lawsuits against the company.
The Affordable Care Act's (aka Obamacare) impact on the healthcare industry.
Other factors - not listed - that led to ISRG's declines in gynecologic and urologic procedures (two of ISRG's largest surgical businesses) in the U.S.
All of the above factors caused ISRG to have disappointing earnings in 2013 and Q1 2014, which led to the stock's substantial decline since 2013 (see image below).

(click to enlarge)


Is Intuitive Surgical an Undervalued Stock or a Value Trap?

While the stock has plunged substantially since 2013, the question you may wonder "is ISRG an undervalued stock that will eventually turn around or a value trap that will continue to have declining earnings?" (I define value trap as a stock that appears to be cheap, but in reality, it is still expensive relative to its intrinsic value.)

First of all, we have to understand that ISRG is no longer a fast-growing company with a revenue CAGR of 30% each year. Assuming that its current negative economic trends (as mentioned earlier) continue through 2014 and 2015, its average revenue growth rate or revenue CAGR for the next decade will likely be in the mid-to-high-single-digit range (e.g. a CAGR of 5 to 10%) and not in the double-digit range (e.g. a CAGR of 10 to 30%).

Secondly, ISRG's da Vinci System sales are largely driven by procedure volume growth in the U.S. and in the international market (e.g. Europe, Japan and Asia). According to the latest Q1 2014 conference call, management is expecting that its overall procedure growth will be impacted by the slowing procedure growth in the U.S. through 2014. Specifically, management stated the company's near term negative economic trend in the Q1 2014 conference call:

"Due to these factors affecting the capital side of our business, we will not be providing a revenue forecast at this time. As mentioned on last quarter's call, we expect to sell fewer systems in 2014 than the 546 systems sold in 2013."

While I do not know how much the Affordable Care Act has impacted hospital budgets, surgical admissions and patents who are willing to take on robotic surgeries, I believe that ISRG's near-term earnings through 2014 and 2015 will be lower than its earnings in 2013, until the U.S. overall procedure growth volume shows greater improvements.

Thirdly, ISRG's da Vinci Surgical System still has a lot of growth opportunities in existing (e.g. gynaecology, urology, general surgery, etc.) and new procedures. While gynaecology is its largest U.S. surgical specialty, general surgery is now the company's fastest growing specialty, according to the Q1 2014 Report. Moreover, the company is investing further in Europe, Japan and other parts in Asia. These international markets are still in their early stages in adopting the da Vinci Surgical System, and they will likely contribute more revenue growth to the company for the next decade as international procedures continue to grow at a faster pace than the U.S.

As mentioned earlier, higher Minimally Invasive Surgery (MIS) procedure growth generally leads to higher system sales and recurring revenue for the company. However, the U.S. procedure growth volume is slowing and the Affordable Care Act has created much uncertainties in the healthcare industry. Hence, I think it is safe to assume that ISRG's revenue growth will likely remain flat or decline throughout 2014 and 2015.

If we consider both ISRG's near-term economic trends and its long-term prospects, I believe that the stock is likely a value trap for the short-term because the company's earnings may disappoint further throughout 2014. However, the company's long-term prospects should remain positive because its da Vinci System sales will pick up once U.S. procedure growth improves.

Intuitive Surgical's Intrinsic Value

I have estimated ISRG's intrinsic value (the company's worth) using three scenarios: optimistic, neutral and pessimistic scenarios (see image below).

(click to enlarge)


Based on my intrinsic value estimate, its current intrinsic value should be around $10 billion in market cap or $256 per share, assuming that the company's free cash flow will grow at a CAGR of 5% each year for the next decade. (Note that this is a pessimistic scenario.) However, if ISRG's free cash flow or net income grows at a CAGR of 10% for the next decade, its current intrinsic value should be around $12 billion in market cap or $315 per share. Either case, I believe that Intuitive Surgical's $13.6 billion market cap or $353 per share (at the time of writing) is still overvalued, even though the stock has dropped substantially since 2013.

Note that my intrinsic value estimates could be too conservative. However, it is possible that ISRG's earnings will continue to disappoint throughout 2014 (for the economic trends that I stated above). This may cause the stock to drop to $10 billion in market cap or $256 per share, which I believe is a fair intrinsic value of the company. It is always better to invest in a company when the stock is close to or below its intrinsic value, so that you are not overpaying for the stock and that there is a good margin of safety in your investment.

The Bottom Line

In the short-term, I believe that ISRG is a value trap because its earnings may disappoint further throughout 2014. The stock is also overvalued based on my intrinsic value estimate. In the long-term, Intuitive Surgical's declining system sales and earnings should eventually recover as U.S. procedure growth volume improves and as the company expands more in new procedures and in the international market.

Sources: Intuitive Surgical 2013 Annual Report, Q1 2014 Report and Conference Call, Morning Star, Yahoo Finance, SA Transcripts and Intelligent Stocks.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

[Renaissance18]

The following is a good read:

http://www.alumni.westernu.ca/alumni-gazette/spring2014/making-human-repairs-with.html#.U2pQtK1dXqo

[OGSPECULATOR]

This chart leaves seasoned traders speechless...

[jimmybob]

ISRG : http://www.sec.gov/Archives/edgar/data/1035267/000103526714000058/exhibit991clearancelette.htm

[GlobalStockChimp]

This stock is one risky stock, it pops and really as quickly drops. As much as many would feel that its probably time to look at it for a long we think otherwise.. It missed analyst expectations on both the top and bottom lines in its 1Q14 results (on 22 April 14).

Sales of its key da Vinci system declined almost 50% led by steep declines in the US market. The company blamed reduced surgical procedures and adjustments in hospital spending on account of the Affordable Care Act as the reasons.

http://goo.gl/m3zAxB

[chickenlips]

Yes saw that.

[was CUIN2]

Bloodbath, sorry to say. But the future for ISRG is not looking to promising either. Need some management changes IMO

[pointofreturn]

Chicken Lips did you see Titan closed the 25 mil financing today ?

Stockwatch News
Today at 10:26 AM
Titan Medical closes $25.62-million financing
Ticker Symbol: C:TMD
Titan Medical closes $25.62-million financing
Titan Medical Inc (C:TMD)
Shares Issued 86,656,251
Last Close 4/22/2014 $2.06
Wednesday April 23 2014 - News Release
Mr. John Hargrove reports
TITAN MEDICAL INC. CLOSES UNIT OFFERING
Titan Medical Inc. has closed its previously announced public offering made pursuant to an agency agreement dated April 10, 2014, between the company and Dundee Securities Ltd. The company has sold a base offering of 10,611,469 units and full overallotment of 1,591,720 units for a total of 12,203,189 units at a price of $2.10 per unit for aggregate gross proceeds of $25,626,697. BayFront Capital Partners Ltd. acted as a selling group member in connection with the offering.
Each unit consists of one common share of the company and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one share of the company at a price of $2.75 for a period of 36 months following the closing date (as defined below).
The offering, as scheduled, closed on April 23, 2014. The units were qualified for sale by way of a prospectus supplement dated April 10, 2014, to the company's short form base shelf prospectus dated Oct. 15, 2012, which has been filed in the provinces of British Columbia, Alberta and Ontario.
The net proceeds of the offering will be used for continuing development and commercialization of robotic surgery technologies and general working capital requirements. The company expects that it now has sufficient funds to see the Sport surgical system through to commercialization.
For further details regarding the offering, please see the company's press releases dated April 7, 2014, and April 8, 2014, respectively, the prospectus and the agency agreement, copies of which are available under the company's profile at SEDAR.
We seek Safe Harbor.
© 2014 Canjex Publishing Ltd.

[chickenlips]

Come on over guys and buy some TITAN (TITXF)

[was CUIN2]

http://www.oncologynurseadvisor.com/robotic-surgery-trends-create-new-career-options-for-nurses/article/341748/


Robotic surgery trends create new career options for nurses

A rather large wave of opportunity is about to arrive for perioperative oncology nurses working in or wanting to learn robotic surgery. The market for robot-assisted minimally invasive surgery (MIS) for prostatectomy, hysterectomy, and other cancer procedures is booming as more hospitals and clinics purchase surgical robots and begin training their surgical teams to operate them. Add to this growth, the impending arrival of new surgical robot manufacturers to compete with the predominate da Vinci Surgical System, and thousands of new positions for perioperative nurses certified in robotics could soon be created.

“In the very near future robotics is simply going to be the way surgeries are performed, and for nurses looking to align their perioperative careers with the future, training for robotic surgery is paramount,” said Marci Trump, surgical robotics coordinator at Long Beach Memorial (LBM) Hospital in Long Beach, California.

Already 4 out of 5 radical prostatectomies in the United States are performed using the da Vinci system from Intuitive Surgical (Sunnyvale, California).1 In a market that is expected to grow from $3.2 billion in 2012 to $20 billion in 2019, as many as 3,000 US hospitals and 5,000 private outpatient surgical clinics are without robotic surgery programs.2,3

Nurses are trained in robotic surgery by their hospitals, and for the last 15 years that training was on the da Vinci system, the only FDA-approved robotic surgical system to date.4 However, its $1.5 million price tag has prohibited many hospitals and clinics from purchasing one and starting their own robotic surgery program, which requires at least two robotic surgery procedures per day to offset the cost of the system.

But the Single Port Orifice Robotic Technology (SPORT) Surgical System, a $700,000 robotic surgical system from Titan Medical (Toronto, Canada), can lower the barrier of entry for hospitals wanting to offer robotic surgical procedures.5 Titan told Oncology Nurse Advisor that the company is excited about the fact that the arrival of SPORT in the United States will create new opportunities for greater team work and collaboration between perioperative nurses and surgeons. SPORT is expected to earn FDA approval in 2015.

A third player in the robotic MIS market, Medrobotics Corporation (Rayham, Massachusetts), maker of the Flex Robotic System, is moving rapidly toward FDA approval to begin marketing its surgical robots in the United States.6 Robots from Titan and Medrobotics are similar to da Vinci in the way they perform MIS, and each have fewer robotic arms than da Vinci. All three manufacturers' robotic surgical systems require at least two nurses certified in the respective robotic surgery system to assist in surgeries.

Trump remembers being one of the first nurses to raise her hand and get onboard LBM's da Vinci program when it began 5 years ago. Nurses have a great deal of influence when it comes to a hospital's decision to invest in a robotics program, and having the nurses onboard with a hospital's decision to begin a robotics program is essential to its success, said Wiley Nifong, MD, associate professor of Cardiothoracic Surgery at the East Carolina Heart Institute, who trains cardiac surgical teams on the da Vinci. Nurses tapped for robotic surgery who take a vested interest in their hospitals' robotics program early on are the ones typically groomed for management roles, such as Robotics Coordinator or Services Coordinator, depending on how a particular hospital assigns its positions. In these management roles nurses, oversee multiple robotic surgical teams and work with the manufacturer to maintain the instruments and perform ongoing peer-to-peer training, he said.

When LBM added a second da Vinci system, Trump became the robotics coordinator for Urology and General Colorectal Robotics at LBM. In December, she became the robotics coordinator for gynecologic surgery. “I was totally unprepared when I first saw a robotic system,” she said. “They are amazing.”

http://www.oncologynurseadvisor.com/robotic-surgery-trends-create-new-career-options-for-nurses/article/341748/

[was CUIN2]

I'd sell 50% of my position and invest in Titan Medical, you'll double your money within 6 weeks...watch.

[Honeycomb777]

Selling 50 shares of ISRG...

can BUY you over 10,200 of TITXF !!